Third Harmonic Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 30
- Market Cap
- $507.5M
- Website
- http://thirdharmonicbio.com
- Introduction
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise
Third Harmonic Bio Inc. focuses on developing THB335, an oral wild-type KIT inhibitor for mast-cell driven diseases, showing potential in treating conditions like CSU and severe asthma. With a strong financial position and accelerated clinical progress, the company aims to address significant market opportunities despite competition and development risks.
Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation
Atlas Venture closed its fourteenth fund, raising $450 million, to continue investing in biotech startups. The firm has launched 16 new companies and recruited 100 executives in the past two years, with nearly 50 ongoing clinical trials. JF Formela will remain active but no longer make new investments.
Chief Medical Officer Conner Edward R. exercised 4,790 shares at a strike of $4.20 and sold ...
Third Harmonic Bio appoints Geoff McDonough, M.D., to its Board of Directors, enhancing operational leadership and clinical/commercial expertise for advancing THB335 into chronic spontaneous urticaria trials.
© Copyright 2025. All Rights Reserved by MedPath